Mastering Agitation Endpoints with Assessment Expertise

July 30, 2025

Consistent, high-quality assessments are essential in agitation trials. In this focused case study, see how CRC’s rater services helped one sponsor manage scale complexity and tight timelines without compromising data integrity.


As part of a broader partnership, CRC led rater training, certification, and ongoing surveillance for a Phase III study evaluating a novel treatment for agitation associated with dementia. With 45 raters across 16 sites, consistency and precision were critical to ensure clean, dependable data.


What you'll learn:


  • How CRC designed and delivered a tailored rater training and certification program
  • Approaches used to manage scale complexity and minimize variability
  • The impact of algorithmic surveillance on rater quality and oversight

Need reliable data? Let’s talk.

< Older Post
Alzheimer's patient with doctor

Seamless Execution Across Early-Phase Alzheimer’s Trials

July 15, 2025
Discover how CRC supported a novel Alzheimer’s program through first-in-human (FIH), Phase Ib/IIa, and OLE trials with precision, urgency, and trusted oversight.
Illustration of active brain neurons highlighting neural pathways

The Expanding Role of GLP-1 Receptor Agonists in CNS Clinical Research

July 1, 2025
GLP-1 receptor agonists may offer a new path for treating addiction and mental health challenges, emerging as a versatile class in CNS clinical research.
Principal investigator and clinical research associate

4 Ways Strategic Site Selection Maximizes the Value Equation

April 10, 2025
In clinical trials, success hinges not just on protocol design and quality data but on choosing the right investigative sites and engaging them effectively. Here are four key reasons why strategic site selection is critical for maximizing value in your clinical trials.
Show More